Real threat to Opdivo’s small-cell chances will come from elsewhere

Submitted by admin on October 16, 2018 - 9:42am

Source:

EP Vantage

News Tags:

Bristol-Myers Squibb

Opdivo

Small-Cell Lung Cancer

FDA

Tecentriq

Roche

Headline:

Real threat to Opdivo’s small-cell chances will come from elsewhere

snippet:

Bristol-Myers Squibb's Opdivo has flunked the Checkmate-331 study, but this is unlikely to lead to the revoking of US approval in this lung cancer setting.

Search form

You are here

Real threat to Opdivo’s small-cell chances will come from elsewhere

Real threat to Opdivo’s small-cell chances will come from elsewhere